Back to User profile » Dr Vardit Dror
Papers published by Dr Vardit Dror:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
Karakiewicz PI, Nott L, Joshi A, Kannourakis G, Tarazi J, Alam M
OncoTargets and Therapy 2016, 9:2855-2863
Published Date: 12 May 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain
Setnik B, Roland CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V
Journal of Pain Research 2015, 8:361-373
Published Date: 9 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide
Setnik B, Roland CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V
Journal of Pain Research 2015, 8:347-360
Published Date: 8 July 2015
![Noteworthy comment: The paper is important because it is the first phase III trial after the registrative trial investigating the role of axitinib in Asian population.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D
OncoTargets and Therapy 2015, 8:1363-1373
Published Date: 8 June 2015